Business Context and Reporting Period
This Form 10-Q covers the quarterly and six-month periods ended June 30, 1995, for OXIS International, Inc. (Note: The input metadata references "GT Biopharma," but the filing text explicitly identifies the registrant as OXIS International, Inc.). The company operates in the biotechnology sector, focusing on superoxide dismutase (bSOD) products, diagnostic assays, and veterinary applications. The financial statements are prepared on a going concern basis, contingent upon the company's ability to secure additional financing.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1995 | Six Months Ended June 30, 1994 |
|---|---|---|
| Total Revenues | $3,212,000 | $1,294,000 |
| Net Loss | $(2,219,000) | $(390,000) |
| Net Loss Per Share | $(0.23) | $(0.08) |
| Operating Cash Flow | $(2,664,000) | $330,000 |
| Cash and Equivalents (End of Period) | $1,069,000 | $1,094,000 |
| Working Capital Deficit | $(722,000) | $(1,046,000) |
| Total Debt (Current + Long-term) | $1,866,000 | $696,000 |
Note: Debt figures include notes payable, current portion of long-term debt, and capital lease obligations.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 148% year-over-year, driven primarily by the inclusion of acquired businesses (OXIS S.A. and IBC) in the 1995 results. Product sales rose from $1.21 million to $3.14 million.
- Expense Surge: Operating expenses increased significantly. Research and Development (R&D) expenses jumped from $420,000 to $2.02 million, and Selling, General, and Administrative (SG&A) expenses rose from $521,000 to $1.49 million, largely due to the consolidation of acquired entities.
- Widening Losses: The net loss expanded from $390,000 to $2.22 million due to the substantial increase in R&D and SG&A outpacing revenue growth.
- Liquidity Improvement: Despite the operating loss, the working capital deficit improved from $1.05 million to $0.72 million following the issuance of $2.04 million in common stock and $1.37 million in short-term notes.
Outlook, Risks, and Management Commentary
- Capital Needs: Management explicitly states the company must raise additional capital during the remainder of 1995 to continue operations. Failure to do so may force a curtailment of operations, reduction of personnel, or potential bankruptcy proceedings.
- Recent Financing: In May 1995, the company raised $2.04 million via private placement of common stock. Subsequent to the period end (July 1995), an additional $1.5 million was raised via Series B Preferred Stock.
- Acquisition Activity: On July 19, 1995, the company acquired Therox Pharmaceuticals, Inc., issuing 1.44 million shares and agreeing to potential contingent payments of up to $2 million based on commercialization success.
- Key Risks:
- Customer Concentration: Significant reliance on Sanofi Winthrop (35% of 1994 revenues). Future sales depend on the success of a Phase III trial for DISMUTEC.
- Regulatory Issues: Potential withdrawal of bSOD products in Spain and regulatory actions in other European countries could adversely affect sales.
- Going Concern: The company has incurred losses for three consecutive years and currently has a working capital deficit.
Investor Verification Checklist
- Verify the status of the ongoing private placement efforts to raise up to $5 million as disclosed in the MD&A.
- Confirm the outcome of the Sanofi Winthrop Phase III trial for DISMUTEC, which is critical for future bSOD revenue.
- Monitor regulatory developments in Spain regarding the withdrawal of bSOD products and the impact on the Spanish licensee.
- Review the terms of the $600,000 note from a major customer and the $766,000 shareholder notes, including interest rates and collateral requirements.
- Assess the integration and financial impact of the Therox Pharmaceuticals acquisition completed in July 1995.